Enterprise Value
45.61M
Cash
18.12M
Avg Qtr Burn
-4.904M
Short % of Float
1.05%
Insider Ownership
43.47%
Institutional Own.
1.07%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Foralumab Details COVID-19 | Phase 2 Initiation | |
Milciclib (pan-CDK inhibitor) Details Solid tumor/s, Hepatocellular carcinoma | Phase 2 Initiation | |
Foralumab (anti-CD3 mAb) Details Multiple sclerosis | Phase 2a Update | |
Foralumab (anti-CD3 mAb) Details Crohns disease | Phase 1b Data readout | |
Intranassal Foralumab (anti-CD3 mAb) Details Neurodegenerative disease, Alzheimer's disease | Phase 1 Update |